Vivaldi Biosciences
Vivaldi Biosciences is focused on developing innovative vaccines using the Delta NS1 platform to protect against epidemic and pandemic viral respiratory diseases, including influenza and COVID-19. Their mission involves creating broad-spectrum, safe, and effective vaccines delivered via nasal spray, leveraging their proprietary Delta NS1 technology to induce strong immune responses.
Industries
Nr. of Employees
small (1-50)
Vivaldi Biosciences
Fort Collins, Colorado, United States
Patents
Recombinant high growth rate influenza virus comprising mutations in M1, NS2, and PB2
US-12350325-B2
View Details
Recombinant high growth rate influenza virus comprising mutations in M1, NS2, and PB2
US-12350325-B2
View DetailsProducts
Nasal spray universal influenza vaccine (Phase 2 clinical program)
A nasal spray vaccine candidate designed to provide broad protection against diverse influenza strains by using a replication-deficient viral vector that induces interferon and expresses influenza antigens.
Preclinical SARS-CoV-2 + universal influenza combination nasal vaccine
A preclinical intranasal combination vaccine candidate designed to simultaneously target SARS-CoV-2 and influenza using the replication-deficient interferon-inducing viral vector backbone.
DelNS1 H5N1
An intranasal, live attenuated, NS1-deleted influenza pandemic prime vaccine designed to generate broad immune responses, block transmission, and provide rapid protection against H5N1 influenza.
DeltaFLU
DeltaFLU is an advanced, self-adjuvanting influenza vaccine administered as a nasal spray for protection against all influenza type A and B viruses, including seasonal strains and emerging strains with pandemic potential.
Delta-19
A nasal spray vaccine designed to provide protection against both Covid-19 and influenza, building on the Delta NS1 vaccine vector technology platform.
Covid-19 / Universal Influenza Vaccine
Preclinical combination vaccine based on the Delta NS1 vector designed to protect against both Covid-19 and universal influenza.
Nasal spray universal influenza vaccine (Phase 2 clinical program)
A nasal spray vaccine candidate designed to provide broad protection against diverse influenza strains by using a replication-deficient viral vector that induces interferon and expresses influenza antigens.
Preclinical SARS-CoV-2 + universal influenza combination nasal vaccine
A preclinical intranasal combination vaccine candidate designed to simultaneously target SARS-CoV-2 and influenza using the replication-deficient interferon-inducing viral vector backbone.
DelNS1 H5N1
An intranasal, live attenuated, NS1-deleted influenza pandemic prime vaccine designed to generate broad immune responses, block transmission, and provide rapid protection against H5N1 influenza.
DeltaFLU
DeltaFLU is an advanced, self-adjuvanting influenza vaccine administered as a nasal spray for protection against all influenza type A and B viruses, including seasonal strains and emerging strains with pandemic potential.
Delta-19
A nasal spray vaccine designed to provide protection against both Covid-19 and influenza, building on the Delta NS1 vaccine vector technology platform.
Covid-19 / Universal Influenza Vaccine
Preclinical combination vaccine based on the Delta NS1 vector designed to protect against both Covid-19 and universal influenza.
Expertise Areas
- Viral vector vaccine development
- Intranasal (mucosal) vaccine delivery
- Interferon-mediated innate immune activation
- Universal influenza vaccine design
Key Technologies
- Replication-deficient attenuated viral vectors
- Intranasal spray delivery
- Interferon-inducing vaccine vectors
- Heterologous antigen expression in viral backbones